Indeed, targeting STAT5 activity can specifically increase the elimination of BCR-ABL+ cells, both primary CML cells in BM as well as CML cells resistant to TKI (120). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.